Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nanobiotix S.A. - ADSs
(NQ:
NBTX
)
4.030
-0.128 (-3.08%)
Streaming Delayed Price
Updated: 3:59 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nanobiotix S.A. - ADSs
< Previous
1
2
3
4
5
6
7
8
9
Next >
Voting Rights and Shares Capital of the Company
January 11, 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
December 27, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
December 21, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
December 08, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 15, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
November 14, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer Patients
November 10, 2022
Via
Benzinga
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
November 10, 2022
Data to be discussed during Nanobiotix Q3 Earnings Call at 8:00AM EST
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
November 09, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Voting Rights and Shares Capital of the Company
November 08, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
November 02, 2022
Multidisciplinary board includes twelve (12) experts from the United States and Europe that will support the development of lead therapeutic candidate NBTXR3
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Present at the Jefferies London Healthcare Conference
October 31, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
October 27, 2022
Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on November 10, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
October 18, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix: Voting Rights and Shares Capital of the Company
October 10, 2022
From
Nanobiotix
Via
Business Wire
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022
September 28, 2022
From
Nanobiotix
Via
Business Wire
Earnings Scheduled For September 28, 2022
September 28, 2022
Companies Reporting Before The Bell • Lilium (NASDAQ:LILM) is expected to report earnings for its second quarter.
Via
Benzinga
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022
September 22, 2022
From
Nanobiotix
Via
Business Wire
Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial
September 22, 2022
Nanobiotix (NASDAQ: NBTX) determined the recommended phase 2 dose (RP2D) of the NBTXR3 combo regime for inoperable locoregional recurrent or recurrent and metastatic head and neck squamous cell...
Via
Benzinga
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy
September 21, 2022
From
Nanobiotix
Via
Business Wire
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024
September 12, 2022
From
Nanobiotix
Via
Business Wire
Nanobiotix: Voting Rights and Shares Capital of the Company
September 08, 2022
From
Nanobiotix
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 08, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
September 08, 2022
Good morning! It's time for another overview of the biggest pre-market stock movers as we see what's happening on Thursday!
Via
InvestorPlace
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
September 07, 2022
Via
Benzinga
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer
September 07, 2022
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences
September 06, 2022
From
NANOBIOTIX
Via
Business Wire
Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022
August 31, 2022
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX: Voting Rights and Shares Capital of the Company
August 09, 2022
From
Nanobiotix
Via
Business Wire
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
August 02, 2022
Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.